{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:50:11Z","timestamp":1790985011711,"version":"4.1.0"},"publisher-location":"Chichester, UK","reference-count":175,"publisher":"John Wiley & Sons, Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1002\/14651858.cd008834.pub2","type":"reference-entry","created":{"date-parts":[[2013,2,23]],"date-time":"2013-02-23T06:02:01Z","timestamp":1361599321000},"source":"Crossref","is-referenced-by-count":45,"title":["Antiplatelet agents for chronic kidney disease"],"prefix":"10.1002","author":[{"given":"Suetonia C","family":"Palmer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Di Micco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Razavian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan C","family":"Craig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlado","family":"Perkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Pellegrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meg J","family":"Jardine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela C","family":"Webster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Zoungas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni FM","family":"Strippoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,2,28]]},"reference":[{"issue":"1","key":"10.1002\/14651858.CD008834.pub2-BIB1|cit1","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S1561-5413(07)60005-2","article-title":"Warfarin versus aspirin in preventing tunneled hemodialysis catheter thrombosis: a prospective randomized study","volume":"9","author":"Abdul-Rahman","year":"2007","journal-title":"Hong Kong Journal of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD008834.pub2-BIB2|cit2","first-page":"93","article-title":"A controlled trial of dipyridamole in human renal transplantation and an assessment of platelet function studies in rejection","volume":"2","author":"Anderson","year":"1974","journal-title":"Clinical Nephrology"},{"issue":"7","key":"10.1002\/14651858.CD008834.pub2-BIB3|cit3","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/BF01468835","article-title":"Prevention of p.o. clotting of av. cimino fistulae with acetylsalicyl acid: Results of a prospective double blind study","volume":"52","author":"Andrassy","year":"1974","journal-title":"Klinische Wochenschrift"},{"issue":"19","key":"10.1002\/14651858.CD008834.pub2-BIB4|cit4","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1016\/j.jacc.2007.03.025","article-title":"Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial","volume":"49","author":"Bhatt","year":"2007","journal-title":"Journal of the American College of Cardiology"},{"issue":"10","key":"10.1002\/14651858.CD008834.pub2-BIB5|cit5","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/j.amjcard.2009.01.342","article-title":"Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISMA] trial)","volume":"103","author":"Dasgupta","year":"2009","journal-title":"American Journal of Cardiology"},{"issue":"18","key":"10.1002\/14651858.CD008834.pub2-BIB6|cit6","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1093\/eurheartj\/ehm274","article-title":"An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial","volume":"28","author":"Wang","year":"2007","journal-title":"European Heart Journal"},{"issue":"1-2","key":"10.1002\/14651858.CD008834.pub2-BIB7|cit7","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1440-1797.1998.tb00316.x","article-title":"A randomized prospective comparison of nadolol, captopril with or without ticlopidine on disease progression in IgA nephropathy","volume":"4","author":"Cheng","year":"1998","journal-title":"Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD008834.pub2-BIB8|cit8","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.ahj.2007.10.046","article-title":"The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial","volume":"155","author":"Best","year":"2008","journal-title":"American Heart Journal"},{"issue":"19","key":"10.1002\/14651858.CD008834.pub2-BIB9|cit9","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","article-title":"Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial","volume":"288","author":"Steinhubl","year":"2002","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD008834.pub2-BIB10|cit10","unstructured":"Creek R Ticlopidine. Patency of haemodialysis access sites Guildford Sanofi Winthrop. Internal report 1990"},{"issue":"2","key":"10.1002\/14651858.CD008834.pub2-BIB11|cit11","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/01.hjr.0000220582.19516.a6","article-title":"Renal function and outcomes in acute coronary syndrome: impact of clopidogrel","volume":"14","author":"Keltai","year":"2007","journal-title":"European Journal of Cardiovascular Prevention & Rehabilitation"},{"issue":"7","key":"10.1002\/14651858.CD008834.pub2-BIB12|cit12","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"New England Journal of Medicine"},{"issue":"18","key":"10.1002\/14651858.CD008834.pub2-BIB13|cit13","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1001\/jama.299.18.2164","article-title":"Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial","volume":"299","author":"Dember","year":"2008","journal-title":"JAMA"},{"issue":"5","key":"10.1002\/14651858.CD008834.pub2-BIB14|cit14","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1191\/1740774505cn118oa","article-title":"Design of the Dialysis Access Consortium (DAC) Clopidogrel Prevention of Early AV Fistula Thrombosis Trial","volume":"2","author":"Dember","year":"2005","journal-title":"Clinical Trials"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD008834.pub2-BIB15|cit15","first-page":"229A","article-title":"Dialysis access consortium (DAC) trial design: clopidogrel prevention of early AV fistula thrombosis [abstract]","volume":"13","author":"Dember","year":"2002","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstract Issue","key":"10.1002\/14651858.CD008834.pub2-BIB16|cit16","first-page":"256A","article-title":"Effect of aspirin (ASA) on primary unassisted graft patency in the dialysis access consortium (DAC) graft trial [abstract]","volume":"19","author":"Dixon","year":"2008","journal-title":"Journal of the American Society of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD008834.pub2-BIB17|cit17","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1191\/1740774505cn110oa","article-title":"Design of the Dialysis Access Consortium (DAC) Aggrenox Prevention Of Access Stenosis Trial","volume":"2","author":"Dixon","year":"2005","journal-title":"Clinical Trials"},{"issue":"Abstract Issue","key":"10.1002\/14651858.CD008834.pub2-BIB18|cit18","first-page":"232A","article-title":"Dialysis Access Consortium (DAC) Trial design: sustained-release dipyridamole plus aspirin (D\/A) to prevent graft failure [abstract]","volume":"10","author":"Dixon","year":"2002","journal-title":"Journal of the American Society of Nephrology"},{"issue":"21","key":"10.1002\/14651858.CD008834.pub2-BIB19|cit19","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1056\/NEJMoa0805840","article-title":"Effect of dipyridamole plus aspirin on hemodialysis graft patency","volume":"360","author":"Dixon","year":"2009","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD008834.pub2-BIB20|cit20","series-title":"Proceedings of the VI International Congress of Mediterranean League Against Thrombosis","article-title":"Ticlopidine preserves vascular access for haemodialysis [abstract 326F]","author":"Dodd","year":"1980"},{"issue":"22","key":"10.1002\/14651858.CD008834.pub2-BIB21|cit21","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1056\/NEJM198405313102203","article-title":"Membranoproliferative glomerulonephritis. A prospective clinical trial of platelet-inhibitor therapy","volume":"310","author":"Donadio","year":"1984","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD008834.pub2-BIB22|cit22","unstructured":"Ell S Mihindukulasuriya JC O'Brien JR Polak A Vernham G Ticlopidine in the prevention of blockage of fistulae and shunts Haemostasis 1982 180"},{"issue":"14","key":"10.1002\/14651858.CD008834.pub2-BIB25|cit23","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1056\/NEJM199404073301402","article-title":"Use of a monoclonal antibody directed against the platelet glycoprotein IIb\/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation","volume":"330","year":"1994","journal-title":"New England Journal of Medicine"},{"issue":"8902","key":"10.1002\/14651858.CD008834.pub2-BIB23|cit24","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0140-6736(94)90007-8","article-title":"Randomised trial of coronary intervention with antibody against platelet IIb\/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators","volume":"343","author":"Topol","year":"1994","journal-title":"Lancet"},{"issue":"6","key":"10.1002\/14651858.CD008834.pub2-BIB24|cit25","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1001\/jama.1997.03550060055036","article-title":"Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb\/IIIa Inhibition for Prevention of Ischemic Complication","volume":"278","author":"Topol","year":"1997","journal-title":"JAMA"},{"issue":"24","key":"10.1002\/14651858.CD008834.pub2-BIB27|cit26","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJM199706123362401","article-title":"Platelet glycoprotein IIb\/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators","volume":"336","year":"1997","journal-title":"New England Journal of Medicine"},{"issue":"15","key":"10.1002\/14651858.CD008834.pub2-BIB26|cit27","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1161\/01.CIR.99.15.1951","article-title":"Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb\/IIIa blockade with abciximab. One-year outcome in the EPILOG trial","volume":"99","author":"Lincoff","year":"1999","journal-title":"Circulation"},{"issue":"9122","key":"10.1002\/14651858.CD008834.pub2-BIB28|cit28","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0140-6736(98)85010-1","article-title":"Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb\/IIIa blockade","volume":"352","year":"1998","journal-title":"Lancet"},{"issue":"9195","key":"10.1002\/14651858.CD008834.pub2-BIB29|cit29","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1016\/S0140-6736(99)10018-7","article-title":"Outcomes at 1 year and economic implications of platelet glycoprotein IIb\/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb\/IIIa Inhibitor for Stenting","volume":"354","author":"Topol","year":"1999","journal-title":"Lancet"},{"issue":"10","key":"10.1002\/14651858.CD008834.pub2-BIB30|cit30","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1001\/jama.1992.03490100090033","article-title":"Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators","volume":"268","year":"1992","journal-title":"JAMA"},{"issue":"1","key":"10.1002\/14651858.CD008834.pub2-BIB31|cit31","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1525-1594.1985.tb04349.x","article-title":"Double-blind randomized trial of the effects of ticlopidine in arteriovenous fistulas for hemodialysis","volume":"9","author":"Fiskerstrand","year":"1985","journal-title":"Artificial Organs"},{"issue":"3","key":"10.1002\/14651858.CD008834.pub2-BIB32|cit32","first-page":"231","article-title":"Prevention of vascular graft lesions in renal transplant recipients with a new antithrombotic agent (Defibrotide): a controlled study","volume":"4","author":"Frasc\u00e0","year":"1986","journal-title":"Life Support System"},{"key":"10.1002\/14651858.CD008834.pub2-BIB33|cit33","first-page":"48","article-title":"Use of defibrotide in renal transplantation in man","volume":"16 Suppl 1","author":"Bonomini","year":"1986","journal-title":"Haemostasis"},{"issue":"6","key":"10.1002\/14651858.CD008834.pub2-BIB34|cit34","first-page":"968","article-title":"A clinical trial with defibrotide in IgA nephritis (IgA-GN) with impaired renal function [abstract]","volume":"10","author":"Frasc\u00e0","year":"1995","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD008834.pub2-BIB35|cit35","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2165\/00044011-199713040-00002","article-title":"Defibrotide treatment and disease progression in patients with IgA nephropathy and impaired renal function at diagnosis","volume":"13","author":"Frasc\u00e0","year":"1997","journal-title":"Clinical Drug Investigation"},{"issue":"4","key":"10.1002\/14651858.CD008834.pub2-BIB36|cit36","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2165\/00044011-199713040-00002","article-title":"Effects of defibrotide treatment in patients with IgA nephropathy and reduced renal function","volume":"13","author":"Frasc\u00e0","year":"1997","journal-title":"Clinical Drug Investigation"},{"issue":"2","key":"10.1002\/14651858.CD008834.pub2-BIB37|cit37","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1093\/oxfordjournals.ndt.a027280","article-title":"Effects of defibrotide treatment in patients with IgA nephropathy and reduced renal function","volume":"11","author":"Frasc\u00e0","year":"1996","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"2","key":"10.1002\/14651858.CD008834.pub2-BIB38|cit38","doi-asserted-by":"crossref","first-page":"57","DOI":"10.4103\/0971-4065.53323","article-title":"Randomized controlled trial of clopidogrel to prevent primary arteriovenous fistula failure in hemodialysis patients","volume":"19","author":"Ghorbani","year":"2009","journal-title":"Indian Journal of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD008834.pub2-BIB39|cit39","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2337\/diabetes.47.3.423","article-title":"Long-term treatment with the dual antithromboxane agent picotamide decreases microalbuminuria in normotensive type 2 diabetic patients","volume":"47","author":"Giustina","year":"1998","journal-title":"Diabetes"},{"key":"10.1002\/14651858.CD008834.pub2-BIB40|cit40","series-title":"ISN XIII International Congress of Nephrology; 1995 Jul 2-6; Madrid (Spain)","first-page":"200","article-title":"Platelet antiaggregants (PA) could decrease the rate of progression of chronic renal failure (CRF) in diabetic patients (DP) treated previously with angiotensin converting enzyme inhibitors (ACEI) [abstract]","author":"Gonzalez","year":"1995"},{"issue":"1","key":"10.1002\/14651858.CD008834.pub2-BIB41|cit41","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3109\/00365598509180223","article-title":"Thromboprophylactic effect of ticlopidine in arteriovenous fistulas for haemodialysis","volume":"19","author":"Gr\u00f6ntoft","year":"1985","journal-title":"Scandinavian Journal of Urology & Nephrology"},{"key":"10.1002\/14651858.CD008834.pub2-BIB42|cit42","series-title":"12th International Congress of Nephrology; 1993 Jun 13-18; Jerusalem (Israel)","first-page":"398","article-title":"Ticlopidine in fistula surgery: double-blind comparison against placebo on the rate of early occlusion of arterio-venous fistulae [abstract]","author":"Gr\u00f6ntoft","year":"1993"},{"issue":"4","key":"10.1002\/14651858.CD008834.pub2-BIB43|cit43","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1080\/003655998750015458","article-title":"Effects of ticlopidine in AV-fistula surgery in uremia. Fistula Study Group","volume":"32","author":"Gr\u00f6ntoft","year":"1998","journal-title":"Scandinavian Journal of Urology & Nephrology"},{"issue":"11","key":"10.1002\/14651858.CD008834.pub2-BIB44|cit44","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1056\/NEJM197909133011103","article-title":"Prevention of thrombosis in patients on hemodialysis by low-dose aspirin","volume":"301","author":"Harter","year":"1979","journal-title":"New England Journal of Medicine"},{"issue":"9118","key":"10.1002\/14651858.CD008834.pub2-BIB45|cit45","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/S0140-6736(98)04311-6","article-title":"Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group","volume":"351","author":"Hansson","year":"1998","journal-title":"Lancet"},{"issue":"12","key":"10.1002\/14651858.CD008834.pub2-BIB46|cit46","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.jacc.2010.02.068","article-title":"Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial","volume":"56","author":"Jardine","year":"2010","journal-title":"Journal of the American College of Cardiology"},{"issue":"1-2","key":"10.1002\/14651858.CD008834.pub2-BIB47|cit47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1055\/s-2007-1023890","article-title":"The Hypertension Optimal Treatment (HOT) study: Results of 12-month treatment related to age","volume":"123","author":"Kolloch","year":"1998","journal-title":"Deutsche Medizinische Wochenschrift"},{"issue":"2","key":"10.1002\/14651858.CD008834.pub2-BIB48|cit48","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1681\/ASN.V122218","article-title":"Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study","volume":"12","author":"Ruilope","year":"2001","journal-title":"Journal of the American Society of Nephrology"},{"issue":"9063","key":"10.1002\/14651858.CD008834.pub2-BIB50|cit49","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/S0140-6736(96)10172-0","article-title":"Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II","volume":"349","year":"1997","journal-title":"Lancet"},{"issue":"7","key":"10.1002\/14651858.CD008834.pub2-BIB49|cit50","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/S0735-1097(98)00130-2","article-title":"Modifiable risk factors for vascular access site complications in the IMPACT II trial of angioplasty with versus without eptifibatide. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis","volume":"31","author":"Mandak","year":"1998","journal-title":"Journal of the American College of Cardiology"},{"issue":"6","key":"10.1002\/14651858.CD008834.pub2-BIB51|cit51","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1056\/NEJM197402072900604","article-title":"Arteriovenous-shunt thrombosis. Prevention by sulfinpyrazone","volume":"290","author":"Kaegi","year":"1974","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD008834.pub2-BIB52|cit52","first-page":"311","article-title":"Platelet inhibitors in human renal homotransplantation: randomized comparison of aspirin versus dipyridamole","volume":"12","author":"Kauffmann","year":"1980","journal-title":"Transplantation Proceedings"},{"issue":"9","key":"10.1002\/14651858.CD008834.pub2-BIB54|cit53","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1097\/01.ASN.0000081661.10246.33","article-title":"Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis","volume":"14","author":"Kaufman","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD008834.pub2-BIB53|cit54","first-page":"291A","article-title":"Combination aspirin plus clopidogrel in the prevention of hemodialysis access graft thrombosis [abstract]","volume":"12","author":"Kaufman","year":"2001","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD008834.pub2-BIB55|cit55","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/003655902753679454","article-title":"A comparative randomized and placebo-controlled short-term trial of aspirin and dipyridamole for overt type-2 diabetic nephropathy","volume":"36","author":"Khajehdehi","year":"2002","journal-title":"Scandinavian Journal of Urology & Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD008834.pub2-BIB56|cit56","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/0049-3848(80)90390-4","article-title":"Antithrombotic therapy with ticlopidine in chronic renal failure patients on maintenance hemodialysis: a multicenter collaborative double blind study","volume":"20","author":"Kobayashi","year":"1980","journal-title":"Thrombosis Research"},{"key":"10.1002\/14651858.CD008834.pub2-BIB58|cit57","first-page":"277","article-title":"Effects of low dose aspirin on thrombovascular accidents during treatment with rHuEpo: a multicentre, controlled, cross-over study [abstract]","volume":"8","author":"Kooistra","year":"1993","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"8","key":"10.1002\/14651858.CD008834.pub2-BIB57|cit58","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1093\/ndt\/9.8.1115","article-title":"Low-dose aspirin does not prevent thrombovascular accidents in low-risk haemodialysis patients during treatment with recombinant human erythropoietin","volume":"9","author":"Kooistra","year":"1994","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD008834.pub2-BIB59|cit59","first-page":"196","article-title":"Use of sulfinpyrazone to prevent thrombus formation in arteriovenous fistulas and bovine grafts of patients on chronic hemodialysis","volume":"22","author":"Michie","year":"1977","journal-title":"Current Therapeutic Research Clinical & Experimental"},{"key":"10.1002\/14651858.CD008834.pub2-BIB60|cit60","unstructured":"Middleton DA Deichsel G The prophylaxis of thrombosis in new arteriovenous dialysis shunts in the arm by low-dose acetylsalicylic acid and dipyridamole Berlin, Germany: Boehringer Ingelheim. Internal report 1992"},{"issue":"2","key":"10.1002\/14651858.CD008834.pub2-BIB61|cit61","doi-asserted-by":"crossref","first-page":"362","DOI":"10.2215\/CJN.03450807","article-title":"Reduced albuminuria with sarpogrelate is accompanied by a decrease in monocyte chemoattractant protein-1 levels in type 2 diabetes","volume":"3","author":"Ogawa","year":"2008","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"11","key":"10.1002\/14651858.CD008834.pub2-BIB62|cit62","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1161\/CIRCULATIONAHA.109.933796","article-title":"Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) Trial","volume":"122","author":"James","year":"2010","journal-title":"Circulation"},{"issue":"20","key":"10.1002\/14651858.CD008834.pub2-BIB63|cit63","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1161\/01.CIR.0000016359.94919.16","article-title":"Benefits and safety of tirofiban among acute coronary syndrome patients with mild to moderate renal insufficiency: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial","volume":"105","author":"Januzzi","year":"2002","journal-title":"Circulation"},{"issue":"7","key":"10.1002\/14651858.CD008834.pub2-BIB64|cit64","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1056\/NEJM199808133390704","article-title":"Inhibition of platelet glycoprotein IIb\/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet Glycoprotein IIb\/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy","volume":"339","year":"1998","journal-title":"New England Journal of Medicine"},{"issue":"1 Pt 2","key":"10.1002\/14651858.CD008834.pub2-BIB65|cit65","first-page":"969","article-title":"Prevention of chronic cyclosporine nephrotoxicity in renal transplantation by picotamide","volume":"23","author":"Quarto Di Palo","year":"1991","journal-title":"Transplantation Proceedings"},{"issue":"8","key":"10.1002\/14651858.CD008834.pub2-BIB66|cit66","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1161\/01.CIR.98.8.734","article-title":"Randomized, placebo-controlled trial of platelet glycoprotein IIb\/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators","volume":"98","author":"Brener","year":"1998","journal-title":"Circulation"},{"issue":"5","key":"10.1002\/14651858.CD008834.pub2-BIB67|cit67","first-page":"255","article-title":"The effect of dipyridamole on the results of allogenic kidney transplantation","volume":"83","author":"Schulze von","year":"1990","journal-title":"Zeitschrift f\u00fcr Urologie und Nephrologie"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD008834.pub2-BIB69|cit68","first-page":"388","article-title":"Antiplatelet therapy in expanded polytetrafluoroethylene (EPTFE) graft thrombosis: results of a randomized double blind study [abstract]","volume":"4","author":"Sreedhara","year":"1993","journal-title":"Journal of the American Society of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD008834.pub2-BIB68|cit69","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/ki.1994.192","article-title":"Anti-platelet therapy in graft thrombosis: results of a prospective, randomized, double blind study","volume":"45","author":"Sreedhara","year":"1994","journal-title":"Kidney International"},{"issue":"2","key":"10.1002\/14651858.CD008834.pub2-BIB70|cit70","first-page":"167","article-title":"A trial to evaluate the efficacy of picotamide in preventing thrombotic occlusion of the vascular access in hemodialysis patients","volume":"8","author":"Mileti","year":"1995","journal-title":"Journal of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD008834.pub2-BIB71|cit71","first-page":"397","article-title":"Hemodialysis vascular graft stenosis may be altered by low-molecular weight dextran (LMD), but not by aspirin (ASA) [abstract]","volume":"3","author":"Taber","year":"1992","journal-title":"Journal of the American Society of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD008834.pub2-BIB72|cit72","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.ahj.2004.12.002","article-title":"The relation of renal function to ischemic and bleeding outcomes with 2 different glycoprotein IIb\/IIIa inhibitors: the do Tirofiban and ReoPro Give Similar Efficacy Outcome (TARGET) trial","volume":"149","author":"Berger","year":"2005","journal-title":"American Heart Journal"},{"issue":"25","key":"10.1002\/14651858.CD008834.pub2-BIB73|cit73","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJM200106213442502","article-title":"Comparison of two platelet glycoprotein IIb\/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization","volume":"344","author":"Topol","year":"2001","journal-title":"New England Journal of Medicine"},{"issue":"20","key":"10.1002\/14651858.CD008834.pub2-BIB74|cit74","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD008834.pub2-BIB75|cit75","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1053\/j.ajkd.2004.11.015","article-title":"First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease","volume":"45","author":"Baigent","year":"2005","journal-title":"American Journal of Kidney Diseases"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD008834.pub2-BIB76|cit76","first-page":"437A","article-title":"Efficacy and safety of simvastatin and safety of low-dose aspirin among patients with chronic kidney disease: final results of the first UK-heart and renal protection (UK-HARP-I) study [abstract]","volume":"13","author":"Baigent","year":"2002","journal-title":"Journal of the American Society of Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD008834.pub2-BIB77|cit77","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1093\/ndt\/9.6.619","article-title":"Effect of aspirin and dipyridamole on proteinuria in idiopathic membranoproliferative glomerulonephritis: a multicentre prospective clinical trial","volume":"9","author":"Z\u00e4uner","year":"1994","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"9038","key":"10.1002\/14651858.CD008834.pub2-BIB78|cit78","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee","volume":"348","year":"1996","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD008834.pub2-BIB79|cit79","doi-asserted-by":"crossref","first-page":"325","DOI":"10.2165\/00002018-199921040-00007","article-title":"Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE. CAPRIE Steering Committee and Investigators. Clopidogrel versus aspirin in patients at risk of ischaemic events","volume":"21","author":"Harker","year":"1999","journal-title":"Drug Safety"},{"issue":"9","key":"10.1002\/14651858.CD008834.pub2-BIB80|cit80","first-page":"1720","article-title":"Haemodynamic changes induced by the correction of anaemia by erythropoietin: role of antiplatelet therapy","volume":"10","author":"Caravaca","year":"1995","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD008834.pub2-BIB81|cit81","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.amjcard.2004.11.003","article-title":"Bivalirudin versus heparin and glycoprotein IIb\/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial)","volume":"95","author":"Chew","year":"2005","journal-title":"American Journal of Cardiology"},{"issue":"6","key":"10.1002\/14651858.CD008834.pub2-BIB82|cit82","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/BF02549745","article-title":"The effect of sulphinpyrazone and alpha-tocopherol on platelet activation and function in haemodialysed patients","volume":"22","author":"Dmoszynska-Giannopoulou","year":"1990","journal-title":"International Urology & Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD008834.pub2-BIB83|cit83","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.amjcard.2008.06.035","article-title":"Usefulness of proteinuria as a prognostic marker of mortality and cardiovascular events among patients undergoing percutaneous coronary intervention (data from the Evaluation of Oral Xemilofiban in Controlling Thrombotic Events [EXCITE] trial)","volume":"102","author":"Mercado","year":"2008","journal-title":"American Journal of Cardiology"},{"issue":"6","key":"10.1002\/14651858.CD008834.pub2-BIB84|cit84","first-page":"306","article-title":"Preventive treatment of patients after non-disabling cerebral ischaemia of presumed arterial origin: Comparative randomized study with intensive anticoagulant therapy or aspirin treatment","volume":"142","author":"Gorter","year":"1998","journal-title":"Nederlands Tijdschrift voor Geneeskunde"},{"issue":"2","key":"10.1002\/14651858.CD008834.pub2-BIB85|cit85","doi-asserted-by":"crossref","first-page":"161","DOI":"10.7326\/0003-4819-136-2-200201150-00016","article-title":"Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force","volume":"136","author":"Hayden","year":"2002","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD008834.pub2-BIB86|cit86","unstructured":"Huang J Investigation of platelet function and aspirin resistance in chronic dialysis patient Available at http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01045785"},{"issue":"1","key":"10.1002\/14651858.CD008834.pub2-BIB87|cit87","first-page":"215","article-title":"Preventive effects of ticlopidine on the incidence of late AV fistula thrombosis complications in haemodialyses patients","volume":"58","author":"Janicki","year":"2003","journal-title":"Annales Universitatis Mariae Curie-Sklodowska - Sectio d - Medicina"},{"issue":"4","key":"10.1002\/14651858.CD008834.pub2-BIB88|cit88","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1159\/000190330","article-title":"Safety of combining ticlopidine with nadroparin in the routine treatment of chronic hemodialysis patients","volume":"77","author":"Kamper","year":"1997","journal-title":"Nephron"},{"issue":"2","key":"10.1002\/14651858.CD008834.pub2-BIB89|cit89","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1177\/089686080902900212","article-title":"Effects of beraprost sodium, an oral prostaglandin i2 analog, on hemostatic factors and inflammation in chronic peritoneal dialysis patients","volume":"29","author":"Kim","year":"2009","journal-title":"Peritoneal Dialysis International"},{"issue":"12","key":"10.1002\/14651858.CD008834.pub2-BIB90|cit90","first-page":"727","article-title":"Comparative study on effect of Panax notoginseng and ticlid in treating early diabetic nephropathy","volume":"18","author":"Lang","year":"1998","journal-title":"Zhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi [Chinese Journal of Integrated Traditional and Western Medicine]"},{"issue":"1","key":"10.1002\/14651858.CD008834.pub2-BIB91|cit91","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1440-1797.1997.tb00201.x","article-title":"Three-year randomized controlled trial of dipyridamole and low-dose warfarin in patients with IgA nephropathy and renal impairment","volume":"3","author":"Lee","year":"1997","journal-title":"Nephrology"},{"issue":"7790","key":"10.1002\/14651858.CD008834.pub2-BIB92|cit92","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/S0140-6736(72)92656-6","article-title":"Reduction of thrombus formation on dialyser membranes by aspirin and RA 233","volume":"2","author":"Lindsay","year":"1972","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD008834.pub2-BIB93|cit93","series-title":"35th Congress, European Renal Association, European Dialysis and Transplantation Association; Rimini (Italy)","first-page":"240","article-title":"Antiplatelet drugs in diabetic hemodialysis patients: comparison of aspirin vs ticlopidine hydrochloride [abstract]","author":"Minakata","year":"1998"},{"issue":"12","key":"10.1002\/14651858.CD008834.pub2-BIB94|cit94","first-page":"44","article-title":"Desaggregation therapy of acute glomerulonephritis","volume":"79","author":"Movchan","year":"2001","journal-title":"Klinicheskaia Meditsina"},{"issue":"4","key":"10.1002\/14651858.CD008834.pub2-BIB95|cit95","first-page":"423","article-title":"Atherosclerotic renovascular disease: medical therapy versus medical therapy plus renal artery stenting in preventing renal failure progression: the rationale and study design of a prospective, multicenter and randomized trial (NITER)","volume":"18","author":"Scarpioni","year":"2005","journal-title":"Journal of Nephrology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008834.pub2-BIB96|cit96","first-page":"A16","article-title":"A randomised controlled trial of cardiovascular risk factor modification in end stage renal failure [abstract]","volume":"9","author":"Perkovic","year":"2004","journal-title":"Nephrology"},{"key":"10.1002\/14651858.CD008834.pub2-BIB97|cit97","first-page":"377A","article-title":"A randomised controlled trial of cardiovascular risk factor modification in end stage kidney disease [abstract]","volume":"15","author":"Perkovic","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"6618","key":"10.1002\/14651858.CD008834.pub2-BIB98|cit98","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1136\/bmj.296.6618.313","article-title":"Randomised trial of prophylactic daily aspirin in British male doctors","volume":"296","author":"Peto","year":"1988","journal-title":"British Medical Journal Clinical Research Ed."},{"issue":"3","key":"10.1002\/14651858.CD008834.pub2-BIB99|cit99","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJM198907203210301","article-title":"Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group","volume":"321","year":"1989","journal-title":"New England Journal of Medicine"},{"issue":"9098","key":"10.1002\/14651858.CD008834.pub2-BIB100|cit100","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0140-6736(97)11475-1","article-title":"Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice Research Framework","volume":"351","year":"1998","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD008834.pub2-BIB101|cit101","first-page":"13","article-title":"Stenting of renal artery stenosis in coronary artery disease (RAS-CAD) study: a prospective, randomized trial","volume":"22","author":"Marcantoni","year":"2009","journal-title":"Journal of Nephrology"},{"issue":"21","key":"10.1002\/14651858.CD008834.pub2-BIB102|cit102","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1161\/CIRCULATIONAHA.107.730259","article-title":"Embolic protection and platelet inhibition during renal artery stenting","volume":"117","author":"Cooper","year":"2008","journal-title":"Circulation"},{"issue":"6","key":"10.1002\/14651858.CD008834.pub2-BIB103|cit103","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1002\/ccd.21932","article-title":"Complete versus partial distal embolic protection during renal artery stenting","volume":"73","author":"Kanjwal","year":"2009","journal-title":"Catheterization & Cardiovascular Interventions"},{"issue":"6","key":"10.1002\/14651858.CD008834.pub2-BIB104|cit104","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/ki.1982.226","article-title":"Augmentation of peritoneal clearance by dipyridamole","volume":"22","author":"Rubin","year":"1982","journal-title":"Kidney International"},{"issue":"1","key":"10.1002\/14651858.CD008834.pub2-BIB105|cit105","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1525-1594.1984.tb04244.x","article-title":"Prevention of platelet deposition and thrombus formation on hemodialysis membranes: a double-blind randomized trial of aspirin and dipyridamole","volume":"8","author":"Salter","year":"1984","journal-title":"Artificial Organs"},{"issue":"6","key":"10.1002\/14651858.CD008834.pub2-BIB106|cit106","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMoa0706245","article-title":"Effect of a multifactorial intervention on mortality in type 2 diabetes","volume":"358","author":"Gaede","year":"2008","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD008834.pub2-BIB107|cit107","first-page":"451","article-title":"Pharmacologic profile of diaspirin crosslinked hemoglobin (DCLHB) in hemodialysis (HD) patients [abstract]","volume":"5","author":"Halstenson","year":"1994","journal-title":"Journal of the American Society of Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD008834.pub2-BIB108|cit108","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/0272-6386(95)90056-X","article-title":"Pharmacologic profile of diaspirin cross-linked hemoglobin in hemodialysis patients","volume":"26","author":"Swan","year":"1995","journal-title":"American Journal of Kidney Diseases"},{"key":"10.1002\/14651858.CD008834.pub2-BIB109|cit109","series-title":"ISN XIII International Congress of Nephrology; 1995 Jul 2-6; Madrid (Spain)","first-page":"559","article-title":"Pharmacodynamic and pharmacokinetic parameters of diaspirin cross-linked hemoglobin (DCLHB) in hemodialysis (HD) patients [abstract]","author":"Swan","year":"1995"},{"issue":"10","key":"10.1002\/14651858.CD008834.pub2-BIB110|cit110","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1093\/ndt\/gfh981","article-title":"Renal function, concomitant medication use and outcomes following acute coronary syndromes","volume":"20","author":"Reddan","year":"2005","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"9201","key":"10.1002\/14651858.CD008834.pub2-BIB111|cit111","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S0140-6736(99)11179-6","article-title":"Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial. The SYMPHONY Investigators. Sibrafiban versus Aspirin to Yield Maximum Protection from Ischemic Heart Events Post-acute Coronary Syndromes","volume":"355","year":"2000","journal-title":"Lancet"},{"issue":"3-4","key":"10.1002\/14651858.CD008834.pub2-BIB112|cit112","first-page":"c128","article-title":"Clopidogrel diminishes hemodialysis access graft thrombosis","volume":"102","author":"Trimarchi","year":"2006","journal-title":"Nephron"},{"issue":"36","key":"10.1002\/14651858.CD008834.pub2-BIB113|cit113","first-page":"1765","article-title":"Prevention of occlusions after bypass surgery with anticoagulant agents or acetylsalicylic acid: a randomised comparison","volume":"145","author":"Zaag","year":"2001","journal-title":"Nederlands Tijdschrift voor Geneeskunde"},{"key":"10.1002\/14651858.CD008834.pub2-BIB114|cit114","first-page":"1472","article-title":"Thromboxane generation by dialysis membranes is controlled by aspirin administration [abstract]","volume":"11","author":"Vienken","year":"1996","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD008834.pub2-BIB115|cit115","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1093\/ndt\/14.5.1097","article-title":"Combined therapy with prednisolone, azathioprine, heparin-warfarin, and dipyridamole for paediatric patients with severe IgA nephropathy - is it relevant for adult patients?","volume":"14","author":"Yoshikawa","year":"1999","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD008834.pub2-BIB116|cit116","first-page":"507","article-title":"The efficacy and complications of aspirin versus heparin in postoperative prophylaxis against thrombosis in newly placed hemodialysis access [abstract]","volume":"6","author":"Zibari","year":"1995","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD008834.pub2-BIB117|cit117","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2369-10-1","article-title":"Preventing AVF thrombosis: the rationale and design of the Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study","volume":"10","author":"Irish","year":"2009","journal-title":"BMC Nephrology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008834.pub2-BIB118|cit118","first-page":"A45","article-title":"High rate of screening failure in the FAVOURED study [abstract]","volume":"14","author":"Irish","year":"2009","journal-title":"Nephrology"},{"key":"10.1002\/14651858.CD008834.pub2-BIB119|cit119","unstructured":"Taipei Veterans General Hospital Taiwan Efficacy of monitoring of aspirin responsiveness in the prevention of cardiovascular events and decrease in bleeding complications in patients with end-stage kidney disease undergoing hemodialysis Available at http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01198379"},{"issue":"3","key":"10.1002\/14651858.CD008834.pub2-BIB120|cit120","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1093\/ndt\/14.3.648","article-title":"Cardiovascular morbidity and risk factors in renal transplant patients","volume":"14","author":"Aakhus","year":"1999","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD008834.pub2-BIB121|cit121","first-page":"S13","article-title":"Special characteristics of atherosclerosis in chronic renal failure","volume":"60 Suppl 1","author":"Amann","year":"2003","journal-title":"Clinical Nephrology"},{"issue":"13","key":"10.1002\/14651858.CD008834.pub2-BIB122|cit122","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1056\/NEJMoa041365","article-title":"Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction","volume":"351","author":"Anavekar","year":"2004","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD008834.pub2-BIB123|cit123","unstructured":"Australia New Zealand Dialysis Transplant Registry The 32nd Annual Report 2009 Report - Data to 2008 http:\/\/www.anzdata.org.au\/v1\/report_2009.html"},{"issue":"7329","key":"10.1002\/14651858.CD008834.pub2-BIB124|cit124","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","year":"2002","journal-title":"BMJ"},{"issue":"9678","key":"10.1002\/14651858.CD008834.pub2-BIB125|cit125","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","author":"Blackwell","year":"2009","journal-title":"Lancet"},{"issue":"7 Suppl 2","key":"10.1002\/14651858.CD008834.pub2-BIB126|cit126","first-page":"S131","article-title":"Prevalence of kidney damage in Australian adults: The AusDiab kidney study","volume":"14","author":"Chadban","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD008834.pub2-BIB127|cit127","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0735-1097(03)00572-2","article-title":"Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction","volume":"42","author":"Berger","year":"2003","journal-title":"Journal of the American College of Cardiology"},{"issue":"4","key":"10.1002\/14651858.CD008834.pub2-BIB128|cit128","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.ahj.2007.10.046","article-title":"The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial","volume":"155","author":"Best","year":"2008","journal-title":"American Heart Journal"},{"key":"10.1002\/14651858.CD008834.pub2-BIB129|cit129","first-page":"48","article-title":"Use of defibrotide in renal transplantation in man","volume":"16 Suppl 1","author":"Bonomini","year":"1986","journal-title":"Haemostasis"},{"key":"10.1002\/14651858.CD008834.pub2-BIB130|cit130","unstructured":"Caring for Australasians with Renal Impairment (CARI) Vascular access http:\/\/www.cari.org.au\/dialysis_va_list_published.php"},{"issue":"9502","key":"10.1002\/14651858.CD008834.pub2-BIB131|cit131","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1016\/S0140-6736(05)67814-2","article-title":"Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis","volume":"366","author":"Casas","year":"2005","journal-title":"Lancet"},{"issue":"9","key":"10.1002\/14651858.CD008834.pub2-BIB132|cit132","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1742-1241.2009.02329.x","article-title":"Antiplatelet agents for the prevention of arteriovenous fistula and graft thrombosis: a meta analysis","volume":"64","author":"Coleman","year":"2010","journal-title":"International Journal of Clinical Practice"},{"issue":"4","key":"10.1002\/14651858.CD008834.pub2-BIB133|cit133","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/00000441-200304000-00002","article-title":"Cardiovascular mortality in end-stage renal disease","volume":"325","author":"Collins","year":"2003","journal-title":"American Journal of the Medical Sciences"},{"issue":"3","key":"10.1002\/14651858.CD008834.pub2-BIB134|cit134","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ccl.2005.04.002","article-title":"Congestive heart failure in chronic kidney disease: disease-specific mechanisms of systolic and diastolic heart failure and management","volume":"23","author":"Curtis","year":"2005","journal-title":"Cardiology Clinics"},{"issue":"16","key":"10.1002\/14651858.CD008834.pub2-BIB135|cit135","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1001\/jama.2009.1488","article-title":"Cardiovascular and noncardiovascular mortality among patients starting dialysis","volume":"302","author":"Jager","year":"2009","journal-title":"JAMA"},{"issue":"3","key":"10.1002\/14651858.CD008834.pub2-BIB136|cit136","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ccl.2005.03.002","article-title":"Pathophysiology of cardiovascular disease and renal failure","volume":"23","author":"Dikow","year":"2005","journal-title":"Cardiology Clinics"},{"issue":"4","key":"10.1002\/14651858.CD008834.pub2-BIB137|cit137","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1161\/01.HYP.0000142248.54761.56","article-title":"The burden of adult hypertension in the United States 1999 to 2000: a rising tide","volume":"44","author":"Fields","year":"2004","journal-title":"Hypertension"},{"issue":"1","key":"10.1002\/14651858.CD008834.pub2-BIB138|cit138","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/ki.1995.22","article-title":"Clinical and echocardiographic disease in patients starting end-stage renal disease therapy","volume":"47","author":"Foley","year":"1995","journal-title":"Kidney International"},{"key":"10.1002\/14651858.CD008834.pub2-BIB139|cit139","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1111\/j.1523-1755.2005.09906.x","article-title":"Chronic renal failure: a cardiovascular risk factor","volume":"99","author":"Fort","year":"2005","journal-title":"Kidney International - Supplement"},{"issue":"13","key":"10.1002\/14651858.CD008834.pub2-BIB140|cit140","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD008834.pub2-BIB141|cit141","unstructured":"GRADE Working Group Grading of Recommendations Assessment, Development and Evaluation (GRADE) http:\/\/www.gradeworkinggroup.org\/index.htm"},{"issue":"7414","key":"10.1002\/14651858.CD008834.pub2-BIB142|cit142","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD008834.pub2-BIB143|cit143","unstructured":"Higgins JP Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"1","key":"10.1002\/14651858.CD008834.pub2-BIB144|cit144","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2215\/CJN.01810407","article-title":"Major bleeding in hemodialysis patients","volume":"3","author":"Holden","year":"2008","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"2","key":"10.1002\/14651858.CD008834.pub2-BIB145|cit145","first-page":"176","article-title":"Cardiovascular disease after renal transplantation","volume":"20","author":"Kasiske","year":"2000","journal-title":"Seminars in Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD008834.pub2-BIB146|cit146","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1525-139X.2006.00179.x","article-title":"Platelet dysfunction and end-stage renal disease","volume":"19","author":"Kaw","year":"2006","journal-title":"Seminars in Dialysis"},{"key":"10.1002\/14651858.CD008834.pub2-BIB147|cit147","unstructured":"National Kidney Foundation KDOQI clinical practice guidelines for cardiovascular disease in dialysis patients http:\/\/www.kidney.org\/professionals\/kdoqi\/guidelines_cvd\/guide3.htm"},{"issue":"6","key":"10.1002\/14651858.CD008834.pub2-BIB148|cit148","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1001\/archinte.164.6.659","article-title":"Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization","volume":"164","author":"Keith","year":"2004","journal-title":"Archives of Internal Medicine"},{"issue":"2","key":"10.1002\/14651858.CD008834.pub2-BIB149|cit149","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1212\/01.wnl.0000229099.62706.a3","article-title":"Renal dysfunction and risk of ischemic stroke or TIA in patients with cardiovascular disease","volume":"67","author":"Koren-Morag","year":"2006","journal-title":"Neurology"},{"issue":"8","key":"10.1002\/14651858.CD008834.pub2-BIB150|cit150","doi-asserted-by":"crossref","first-page":"629","DOI":"10.7326\/0003-4819-134-8-200104170-00007","article-title":"Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial","volume":"134","author":"Mann","year":"2001","journal-title":"Annals of Internal Medicine"},{"issue":"2","key":"10.1002\/14651858.CD008834.pub2-BIB151|cit151","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1067\/mhj.2002.125513","article-title":"Benefits of aspirin and beta-blockade after myocardial infarction in patients with chronic kidney disease","volume":"144","author":"McCullough","year":"2002","journal-title":"American Heart Journal"},{"issue":"1","key":"10.1002\/14651858.CD008834.pub2-BIB152|cit152","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1001\/jama.289.1.76","article-title":"Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001","volume":"289","author":"Mokdad","year":"2003","journal-title":"JAMA"},{"issue":"5","key":"10.1002\/14651858.CD008834.pub2-BIB153|cit153","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.0894-0959.2004.17351.x","article-title":"Use of low molecular weight heparins and glycoprotein IIb\/IIIa inhibitors in patients with chronic kidney disease","volume":"17","author":"Mosenkis","year":"2004","journal-title":"Seminars in Dialysis"},{"key":"10.1002\/14651858.CD008834.pub2-BIB154|cit154","unstructured":"National Health and Nutrition Examination Survey http:\/\/www.cdc.gov\/nchs\/nhanes.htm"},{"issue":"5","key":"10.1002\/14651858.CD008834.pub2-BIB155|cit155","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1053\/j.ajkd.2006.08.004","article-title":"Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial","volume":"48","author":"Norris","year":"2006","journal-title":"American Journal of Kidney Diseases"},{"issue":"1","key":"10.1002\/14651858.CD008834.pub2-BIB156|cit156","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1046\/j.1523-1755.2000.00816.x","article-title":"Long-term survival in renal transplant recipients with graft function","volume":"57","author":"Ojo","year":"2000","journal-title":"Kidney International"},{"issue":"4","key":"10.1002\/14651858.CD008834.pub2-BIB157|cit157","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002786.pub2","article-title":"Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts","author":"Osborn","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"12","key":"10.1002\/14651858.CD008834.pub2-BIB158|cit158","doi-asserted-by":"crossref","first-page":"840","DOI":"10.7326\/0003-4819-147-12-200712180-00004","article-title":"Meta-analysis: vitamin D compounds in chronic kidney disease","volume":"147","author":"Palmer","year":"2007","journal-title":"Annals of Internal Medicine"},{"issue":"4","key":"10.1002\/14651858.CD008834.pub2-BIB159|cit159","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1525-139X.2008.00457.x","article-title":"Cardiac problems in the dialysis patient: beyond coronary disease","volume":"21","author":"Remppis","year":"2008","journal-title":"Seminars in Dialysis"},{"issue":"8596","key":"10.1002\/14651858.CD008834.pub2-BIB160|cit160","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/S0140-6736(88)92019-3","article-title":"Bleeding in renal failure","volume":"1","author":"Remuzzi","year":"1988","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD008834.pub2-BIB161|cit161","unstructured":"Renal Association Cardiovascular disease in CKD http:\/\/www.renal.org\/Clinical\/GuidelinesSection\/CardiovascularDiseaseInCKD.aspx#Rationale3"},{"issue":"2","key":"10.1002\/14651858.CD008834.pub2-BIB162|cit162","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1681\/ASN.V122218","article-title":"Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study","volume":"12","author":"Ruilope","year":"2001","journal-title":"Journal of the American Society of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD008834.pub2-BIB163|cit163","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1161\/01.HYP.0000102971.85504.7c","article-title":"Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention","volume":"42","author":"Sarnak","year":"2003","journal-title":"Hypertension"},{"issue":"2","key":"10.1002\/14651858.CD008834.pub2-BIB164|cit164","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1179\/acb.2008.63.2.003","article-title":"Medications in the kidney","volume":"63","author":"Scheen","year":"2008","journal-title":"Acta Clinica Belgica"},{"issue":"7387","key":"10.1002\/14651858.CD008834.pub2-BIB165|cit165","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1136\/bmj.326.7387.472","article-title":"Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses","volume":"326","author":"Song","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD008834.pub2-BIB166|cit166","unstructured":"Sterne JA Egger M Moher D (editors) Chapter 10: Addressing reporting biases. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Intervention Version 5.1.0 [March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"4","key":"10.1002\/14651858.CD008834.pub2-BIB167|cit167","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/s10157-006-0433-8","article-title":"Meta-analysis of antiplatelet therapy for IgA nephropathy","volume":"10","author":"Taji","year":"2006","journal-title":"Clinical & Experimental Nephrology"},{"key":"10.1002\/14651858.CD008834.pub2-BIB168|cit168","unstructured":"US Renal Data System USRDS 2010 Annual Data Report. Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD http:\/\/www.usrds.org\/atlas10.aspx"},{"issue":"1","key":"10.1002\/14651858.CD008834.pub2-BIB169|cit169","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1681\/ASN.2007030308","article-title":"Chronic kidney disease increases risk for venous thromboembolism","volume":"19","author":"Wattanakit","year":"2008","journal-title":"Journal of the American Society of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD008834.pub2-BIB170|cit170","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1097\/01.ASN.0000123691.46138.E2","article-title":"Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies","volume":"15","author":"Weiner","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD008834.pub2-BIB171|cit171","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1053\/j.ajkd.2004.04.024","article-title":"Kidney disease as a risk factor for recurrent cardiovascular disease and mortality","volume":"44","author":"Weiner","year":"2004","journal-title":"American Journal of Kidney Diseases"},{"issue":"3","key":"10.1002\/14651858.CD008834.pub2-BIB172|cit172","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1053\/j.ajkd.2006.05.021","article-title":"Cardiovascular outcomes and all-cause mortality: exploring the interaction between CKD and cardiovascular disease","volume":"48","author":"Weiner","year":"2006","journal-title":"American Journal of Kidney Diseases"},{"issue":"3","key":"10.1002\/14651858.CD008834.pub2-BIB173|cit173","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1161\/01.ATV.11.3.733","article-title":"Defects in platelet adhesion and aggregate formation in uremic bleeding disorder can be attributed to factors in plasma","volume":"11","author":"Zwaginga","year":"1991","journal-title":"Arteriosclerosis & Thrombosis"},{"issue":"1","key":"10.1002\/14651858.CD008834.pub2-BIB174|cit174","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1053\/j.ajkd.2012.08.031","article-title":"Antiplatelet therapy to prevent hemodialysis vascular access failure: systematic review and meta-analysis","volume":"61","author":"Palmer","year":"2013","journal-title":"American Journal of Kidney Diseases"},{"issue":"11","key":"10.1002\/14651858.CD008834.pub2-BIB175|cit175","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD008834","article-title":"Antiplatelet agents for chronic kidney disease","author":"Razavian","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD008834.pub2\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T11:29:10Z","timestamp":1714994950000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD008834.pub2"}},"subtitle":[],"editor":[{"given":"Suetonia C","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2013,2,28]]},"references-count":175,"aliases":["10.1002\/14651858.cd008834.pub3"],"URL":"https:\/\/doi.org\/10.1002\/14651858.cd008834.pub2","relation":{},"subject":[],"published":{"date-parts":[[2013,2,28]]}}}